Boston Scientific temporarily paused enrolment in its AVANT GUARD trial in October to “assess a few unanticipated ...

Late last month, Boston Scientific announced it was pausing a study examining pulsed field ablation as a first-line therapy.

Johnson & Johnson MedTech will enter the U.S. pulsed field ablation market following an FDA green light for its Varipulse ...

The technology is integrated with company’s electroanatomical mapping system, which helps guide operators during AF ablation.

The VARIPULSE™ Platform is the first and only Pulsed Field Ablation (PFA) System in the U.S. fully integrated with the CARTO™ ...

Boston Scientific is resuming its "Avant Guard" study of pulse field ablation (PFA) as a first-line therapy for atrial ...

Johnson & Johnson MedTech, a global leader in cardiac arrhythmia treatment, today announced the U.S. Food & Drug Administration (FDA) approval of the VARIPULSE™ Platform for the treatment of drug ...

Boston Scientific expects to complete enrollment in the coming months in the study comparing pulsed field ablation to ...

Cortex adds to Boston Scientific’s electrophysiology portfolio amid treatment shifts in the space driven by new pulsed field ...

The VARIPULSE™ Platform is the first and only Pulsed Field Ablation (PFA) System in the U.S. fully integrated with the CARTO™ 3 Electro-anatomical Mapping System, driving efficiency ...

The device, Varipulse, is a pulsed field ablation system which uses small burns or freezes to cause some scarring in the ...

Johnson & Johnson MedTech announced today that the FDA approved its Varipulse pulsed field ablation (PFA) platform for ...